The MCG at UMSL represents a collective 35 years of pharmaceutical industry experience. Our chemists have demonstrated expertise in the design, synthesis and development of drug candidates with the prerequisite efficacy, safety, pharmaceutical, pharmacokinetic and pharmacodynamic properties. They also have extensive experience in evaluating and writing pharmaceutical based patents. Our medicinal chemists are experienced at identifying and synthesizing tool or early lead compounds and utilizing structure-based drug design and practical medicinal chemistry experience to transform leads into promising pre-clinical candidates. They are also skilled at synthetic route optimization, scale-up synthesis and working with other contract research organizations (CRO). The MCG works closely with UMSL scientists and draws on the strong synthetic expertise within the Chemistry department and the Center for Nanosciences.
Michael J. Hayes, M.S., Research Scientist, Medicinal Chemistry Group at the University of Missouri-St. Louis
Utilizing his twelve years of industrial experience with Pfizer, Michael is a highly skilled medicinal and synthetic organic chemist. In addition to extensive experience in the design and synthesis of bioactive molecules, he has routinely performed multi-step, combinatorial, and scale-up synthesis of numerous drug candidates. During his time in the pharmaceutical industry, Michael worked on multiple therapeutic targets such as kinases, cannabinoids, synthases, and glucocorticoid receptor modulators for the treatment of inflammatory diseases. Incorporation of traditional structure activity relationship (SAR) analysis, and computer software based design tools with his expertise in the laboratory, make Michael a highly valued member of the team. Michael earned both a B.S. and M.S. degree in Chemistry from Illinois State University. He has co-authored 9 peer reviewed publications and been granted 10 patents and patent publications.